

## Beyond the Guidelines: Clinical Investigator Perspectives on the Management of Breast Cancer (Webinar Video Proceedings)

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following patients with previously treated advanced breast cancer in the DESTINY-Breast04 trial were half as likely to experience disease progression or death with trastuzumab deruxtecan therapy as patients who received chemotherapy?
  - a. Only patients with hormone receptor (HR)-positive disease
  - b. Only patients with a HER2 IHC score of 2+
  - c. The entire intent-to-treat population
  - d. None of the above
2. Which of the following groups of patients in the RxPONDER trial with HR-positive, HER2-negative breast cancer, 1 to 3 positive nodes and a 21-gene Recurrence Score® of  $\leq 25$  derived a benefit in invasive disease-free survival from the addition of chemotherapy to adjuvant endocrine therapy?
  - a. Premenopausal women only
  - b. Postmenopausal women only
  - c. Both premenopausal and postmenopausal women
  - d. Neither postmenopausal nor premenopausal women
3. Updated analysis of event-free survival from the KEYNOTE-522 trial evaluating the addition of pembrolizumab to neoadjuvant chemotherapy and its continuation after surgery for patients with high-risk localized triple-negative breast cancer (TNBC) demonstrated the greatest benefit in which of the following patient populations?
  - a. Patients with node-negative disease
  - b. Patients with node-positive disease
  - c. Patients with Stage II disease
  - d. Patients with Stage III disease
  - e. Benefit was generally consistent across all prespecified subgroups
4. The ongoing Phase III TROPICS-02 study is evaluating sacituzumab govitecan versus treatment of physician's choice for patients with \_\_\_\_\_.
  - a. Localized TNBC
  - b. Advanced TNBC
  - c. Localized ER-positive, HER2-negative breast cancer
  - d. Advanced ER-positive, HER2-negative breast cancer
5. What is the target of datopotamab deruxtecan?
  - a. NTRK
  - b. PARP
  - c. PD-1
  - d. TROP2